DETAILED DRUG EVALUATION OF TREATMENT STRATEGIES FOR CHEMOTHERAPEUTICAGENTS NIH GUIDE, Volume 23, Number 12, March 25, 1994 RFP AVAILABLE: NCI-CM-57207-30 P.T. Keywords: National Cancer Institute The Developmental Therapeutics Program (DTP), Division of Cancer Treatment (DCT), National Cancer Institute (NCI) is seeking a contractor to evaluate compounds for anticancer activity in experimental in vivo tumor models. Studies will focus on agents identified by the Program's disease-oriented in vitro drug screen and will employ human tumors growing in immune-deficient (e.g., athymic, SCID) mice. Experiments will be designed and conducted to optimize drug activity and evaluate the drug's therapeutic potential. Some in vivo studies may involve murine tumors growing in pathogen-free immune-competent rodents, and some cell culture support will be required for propagation of selected human tumors. Results from the project will be interrelated with pharmacokinetic, toxicologic, biochemical and immunologic information to devise and recommend treatment strategies for clinical trials and will be included in investigational New Drug Applications. Compounds to be studied will be selected and assigned by the Government. As compounds of a commercially confidential nature may be evaluated, pharmaceutical and chemical companies will be excluded from the competition. Also, since structural formulae of confidential materials may be provided by the Government on occasion, the organization must be willing to sign a confidentiality of information statement. The organization will provide facilities for handling pathogen-free immune-competent and immune-deficient rodents and utilize methods to protect the facilities from pathogenic organisms. The contract also shall provide facilities/equipment for frozen storage of tumors, tumor transplantation, drug preparation, and treatment, facilities/equipment for the handling of potentially carcinogenic or hazardous materials; facilities/equipment for propagation and testing human and murine tumor lines in vitro. The Principal Investigator should have an M.D.; D.V.M.; or Ph.D. in one of the relevant biological sciences (or equivalent experience), managerial experience, and experience in either managing an in vivo screening program utilizing small animals or evaluating the efficacy or toxicity of antitumor agents, should understand the principles of cancer chemotherapy, and devote approximately 25 percent of his/her time to the project. It is anticipated that one incrementally funded contract will be awarded for a base period of three years, with two one year options. The contract will be written on a level-of-effort basis, specifying that the contractor is to furnish 64,000 labor hours over five years. RFP No. NCI-CM-57207-30 will be available on or about March 31, 1994. Responses will be due May 20, 1994. INQUIRIES Copies of the RFP may be obtained by sending a written request to: Ms. Elsa B. Carlton Research Contracts Branch National Cancer Institute Executive Plaza South, Room 603 Bethesda, MD 20892 Telephone: (301) 496-8620 No collect calls will be accepted. .
Return to NIH Guide Main Index
Office of Extramural Research (OER) |
National Institutes of Health (NIH) 9000 Rockville Pike Bethesda, Maryland 20892 |
Department of Health and Human Services (HHS) |
||||||||
Note: For help accessing PDF, RTF, MS Word, Excel, PowerPoint, Audio or Video files, see Help Downloading Files. |